{"name":"Mathew S. Maurer, MD","slug":"mathew-s-maurer-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizwJBVV95cUxPWEVhSVNtNEY0VUhRZV9tQWFzaW5ybG4yUHJEMUpnU1VidFREcEowTFVnQ0g2V0VpS3VFZ3g0eGlCSlRtbkhoakI5U0dzamhld3c1SkZGUVdRNGtsNVNCS0kzYy12SkI5U29FUFJTRkJlM3AxR1EyZ3M3S0EtdlE0VDFBSlBZOU5ZRDQ5R21GTXExNFhRc293YXlLU2FDNVVQT1BNUnZJYk9VNVJvTHhSbzdnZmlrTHRUejhMVC1kUXRlRGl1UG8yd2x6U1VBTWJ4OEl6dVJlWWtlZUc5TDhLcUNjQlRhai1Ib2hsc0RUSUF0YWcyX2ExSThrQzcwcGtNR1h3ZzNwa2k5THNjMTVOZGN4eFQyM1A0Q1I4OGdFMDI3MUhQc2pKR29DVlg0RzhSRnprT2Nkc3FUR1hGQTJpRF9OUFFhUTVSZC1EUHptMA?oc=5","date":"2025-12-16","type":"regulatory","source":"newswire.ca","summary":"Alnylam Announces Health Canada Approval of AMVUTTRA® (vutrisiran), the First and Only RNAi Therapeutic for the Treatment of Cardiomyopathy in Adult Patients with ATTR Amyloidosis - newswire.ca","headline":"Alnylam Announces Health Canada Approval of AMVUTTRA® (vutrisiran), the First and Only RNAi Therapeutic for the Treatmen","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE52cnY2MU50UExNV3Z1NnVEcHBNTHBtRTRQaHlXRjYycTBCRVhvaGFFMkxOV1gyZ281cWtndE9EZm5RQll0SkJQdUpPcnhjT2NFdFUwUjdrMXRKTmhTaHVGS0JZd0o5R0hILV9FYzQ3aXJQRHpZdHc4UQ?oc=5","date":"2025-11-10","type":"trial","source":"American Heart Association Journals","summary":"Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial - American Heart Associ","headline":"Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE5xZmVidDdVaFM2c3lUUG43M3V5cGo5aVVDbDVaX1FBWENPTTNmZV9LamJ4aC1hWnluZkZaOGpkWnVTcXlLWlMxVzlyZnl1b04xM2pJUDAyU1FoeC0zU1dSbW4xNXFIX0RMdE8yaDA1SHphcXRrdHUzVzNnQQ?oc=5","date":"2025-02-18","type":"pipeline","source":"American Heart Association Journals","summary":"Guideline-Directed Medical Therapy for Heart Failure in Transthyretin Amyloid Cardiomyopathy - American Heart Association Journals","headline":"Guideline-Directed Medical Therapy for Heart Failure in Transthyretin Amyloid Cardiomyopathy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTFBQeXA5VkM1X1ZyOGhtS0l3TmJnRW5aYnFrcWVib3M4aExzeGJ3dlJQbU5uT2R5T1lsWEtaMHlKU0tvOVllVGtDdzFMTmF4TlJ5aHd1eVFYZC0wU2tPcGxtTg?oc=5","date":"2025-01-22","type":"trial","source":"JACC Journals","summary":"Worsening of Heart Failure in Outpatients With Transthyretin Amyloidosis and Cardiomyopathy in the APOLLO-B Trial - JACC Journals","headline":"Worsening of Heart Failure in Outpatients With Transthyretin Amyloidosis and Cardiomyopathy in the APOLLO-B Trial","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE9xWHRnbkRYNENVOWZKOVVqOTFtcjhSNm9ORzFNODUzRHE0OG0zckJwVnZLZmxOU2g1VFJpMWN5WHkzc1p3c1JWWG5Ca2F4a19VZlVwVHJtTWp1cENJVXQzWVhWZzlYc3lmZlZWa2tVNFg4ZmM?oc=5","date":"2024-11-18","type":"regulatory","source":"American Heart Association Journals","summary":"Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial | Circulation - American Heart Association Journals","headline":"Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPcjFwMHZLbjUzMTRkc3pkSHI1ZERWSGtqcG1ucmxBZTd4UUdRZkpBSXBHV0M0Y00tLVd5a2NYYm9OZlZZUm9EX0lPRHF1c01jVGJjX2lWSXhXWHBUVnpQeDdPeWVIX21EcWVVdkRDZFpsSGhQVlNpTzZGRDhPR2hrZEw5V05UclI3ejhISTZ4NA?oc=5","date":"2024-10-04","type":"trial","source":"TCTMD.com","summary":"Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM - TCTMD.com","headline":"Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxNTjhZTUdOV3FaemhwUlQyWEp4WWc4X3N3ZjhKUmRTdjltakRDTjJmcG4ycV9LUTdIb01KTE1xREhmSGE5eGdCQ3dxczhRUTlFWkRvYWJRR1dpZUsxYmlBamo1TkdHS1I1OG5ZbDZKNF9ZT1RRcFFYV3dDWXRycUhpc1FQZHNHa2VCdFpSSUFEaFNQMVJxYV9UeDZhTENTSFZxNmZvNkFwVWVwME12YUNRTHFPUjhxb21GZjJyaDdVeHI1Rk9KVlY0SmhjTy0?oc=5","date":"2024-03-29","type":"pipeline","source":"American College of Cardiology","summary":"Feature | Cardiac Amyloidosis and How to Stop Missing the Diagnosis - American College of Cardiology","headline":"Feature | Cardiac Amyloidosis and How to Stop Missing the Diagnosis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE5MdnUtT2lmaWQ1Y3RHel9wWlNBSnBaREVkNXYySHVTd2dHNEV4SXBVckprUUw4WkZ4SXUyWWFaY25XZ19ZWXhpcHVWSndFelF1UWRCM3BxZmhsbUtVamxzYQ?oc=5","date":"2024-01-10","type":"pipeline","source":"NEJM","summary":"Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy - NEJM","headline":"Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE5NaXFFMHc1amNTNlhUeGQwLVloa2cyUWcwcU9JeXRWblA2WC1DQy1KZFlET0lGcHBNb2xHV2hUV1JzLU1FellvTnpZRENPSUtkdFVaT1FROUZsX0RfbVFyQg?oc=5","date":"2023-10-25","type":"pipeline","source":"NEJM","summary":"Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis - NEJM","headline":"Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTFB2ZF9fVmd4V3RWV3dRYUpMeE9Td1FuYzFBam5nbW9RM2RuS1Y0T1RGYjdDc2JJanp2LXdvb213TkYwMXNSY0t1X1BEYl9DRC1aUzJ4UHdYZy1qOHdlSkhzYjFYaWh4NEJWYVJwNXluU0YwdlhNZkdvdVB0Ykk?oc=5","date":"2022-08-31","type":"pipeline","source":"Medical Xpress","summary":"Common back ailment could be sign of heart failure - Medical Xpress","headline":"Common back ailment could be sign of heart failure","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE4zQXhLaWdYY0FvYTJwZWFhajJBX2NJQzlYOUYyaHNUd1JBYVNtTlJCelNGbTllelQ1a0NsOGhWWHNBUVh3Y0RkYi1CaXcyTkc0MlB3a205TXFpWFVNX0NxXw?oc=5","date":"2018-08-27","type":"pipeline","source":"NEJM","summary":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy - NEJM","headline":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOeEZ1OG4yWlV4blo3TG9sOG9BTkthcDktSEFyMXFFeTZ2M3NtcFBFY1lrMTEwYmUwLWx3eEtwZ2JLZUdabzRJRHNmZk8xUzJBdDZldUUzalBmaHZjSjFEa0tTcVk3SUpKNnloaWRvLXZnU19mVmdBVXAzcGo5YkN2VG1HV25wOGsxSkJJb20wOWI5T2FWbXp6WA?oc=5","date":"2016-08-24","type":"pipeline","source":"Columbia University Irving Medical Center","summary":"Amyloid-Related Heart Failure Now Detectable with Imaging Test - Columbia University Irving Medical Center","headline":"Amyloid-Related Heart Failure Now Detectable with Imaging Test","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}